Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy

BACKGROUND: Sunitinib represents a widely used therapy for metastatic renal cell carcinoma patients. Even so, there is a group of patients who show toxicity without clinical benefit. In this work, we have analysed pivotal molecular targets involved in angiogenesis (vascular endothelial growth factor...

Descripción completa

Detalles Bibliográficos
Autores principales: del Puerto-Nevado, L, Rojo, F, Zazo, S, Caramés, C, Rubio, G, Vega, R, Chamizo, C, Casado, V, Martínez-Useros, J, Rincón, R, Rodríguez-Remírez, M, Borrero-Palacios, A, Cristóbal, I, Madoz-Gúrpide, J, Aguilera, O, García-Foncillas, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037833/
https://www.ncbi.nlm.nih.gov/pubmed/24786599
http://dx.doi.org/10.1038/bjc.2014.225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037833/
https://www.ncbi.nlm.nih.gov/pubmed/24786599
http://dx.doi.org/10.1038/bjc.2014.225

Ejemplares similares